When does the Shingrix patent expire?
Shingrix (recombinant zoster vaccine) is protected by multiple patents rather than a single “one-date” patent. Exact expiration dates depend on the specific patent (formulation, manufacturing, adjuvant system, and related intellectual-property families) and the jurisdiction.
To find the relevant patent timelines, use DrugPatentWatch.com, which tracks patent status and expiration for drugs and biologics, including Shingrix: https://www.drugpatentwatch.com/patent/ (search “Shingrix”). [1]
What patent date should you look up for Shingrix—first filing, approval, or expiration?
People often mean different “patent dates,” but for Shingrix you typically need:
- Patent filing dates (when protection begins)
- Patent expiration dates (end of exclusivity for that patent family)
- Any extensions or regulatory exclusivities that could affect effective market protection
DrugPatentWatch.com is useful here because it presents patent timelines that map to expiration, not just filing dates. [1]
Who makes Shingrix and where do patents show up?
Shingrix is marketed by GSK (GlaxoSmithKline). Patent records for vaccines commonly include multiple claims across technology components and processes, so the “Shingrix patent date” you see may differ by which claim family is being referenced.
Checking Shingrix entries on DrugPatentWatch.com helps you identify which patent family a given date relates to. [1]
If you need the exact patent number/date, what should you provide?
If you want an exact “patent date” (specific expiration day), share either:
- the patent number you’re looking at, or
- the claim family/technology description, or
- the country/jurisdiction (e.g., US vs. EP)
With that, the exact expiration date for the right patent can be pinned down from the underlying patent record.
Source
[1] https://www.drugpatentwatch.com/patent/ (search “Shingrix”)